Want to see FEMY full AI Analyst Report?
Top Page
Femasys
(NASDAQ:FEMY)
Select Model
Select Model
Rating:44Neutral
Price Target:
$2.50
▼(-32.61% Downside)
Action:Reiterated
Date:08/11/26
The score is weighed down primarily by very weak financial performance—large ongoing losses and substantial negative free cash flow relative to a small revenue base—alongside bearish technicals with the stock trading well below key moving averages. Valuation is difficult to support with a negative P/E and no dividend data. Corporate events modestly help by reducing listing risk (Nasdaq compliance) and reinforcing governance stability, but they do not offset the core cash burn and scaling challenges.
Positive Factors
Revenue growth with solid gross margins
Femasys has shown multi-year top-line expansion (revenue rose to ~$2.38M TTM) while maintaining gross margins around 50–67%. Sustained positive gross margins imply the product economics can support scaling commercial efforts and higher utilization without margin deterioration if fixed costs are controlled.
Negative Factors
Sustained heavy cash burn
Cash generation is deeply negative and worsening, implying persistent funding needs. Continued ~-$18M annual cash outflows constrain organic investment in commercial expansion and R&D, increase dilution or debt risk over a multimonth horizon, and limit flexibility until cash flow turns positive.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth with solid gross margins
Femasys has shown multi-year top-line expansion (revenue rose to ~$2.38M TTM) while maintaining gross margins around 50–67%. Sustained positive gross margins imply the product economics can support scaling commercial efforts and higher utilization without margin deterioration if fixed costs are controlled.
Read all positive factors
Femasys (FEMY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.03M
Dividend YieldN/A
Average Volume (3M)47.64K
Price to Earnings (P/E)―
Beta (1Y)0.80
Revenue Growth39.88%
EPS Growth64.70%
CountryUS
Employees53
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-6.43
Shares Outstanding3,019,534
10 Day Avg. Volume57,656
30 Day Avg. Volume47,638
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)3.88
Price to Sales (P/S)9.93
P/FCF Ratio-1.19
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$30.00Price Target Upside708.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-4.33
Revenue Forecast (FY)$3.77M
Femasys Business Overview & Revenue Model
Company Description
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as F...
How the Company Makes Money
Femasys generates revenue primarily from the sale of its women’s health medical devices and related consumable/disposable products used in clinical and office-based gynecology and fertility procedures. Key revenue streams include (1) FemVue produc...
Femasys Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
54
Neutral
Cash Flow
16
Very Negative
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.29M | 1.63M | 1.07M | 1.21M | 1.18M |
| Gross Profit | 1.42M | 1.08M | 691.90K | 764.28K | 809.30K |
| EBITDA | -15.89M | -16.33M | -13.17M | -10.49M | -6.55M |
| Net Income | -18.63M | -18.82M | -14.25M | -11.39M | -7.54M |
Balance Sheet | |||||
| Total Assets | 20.72M | 12.45M | 27.76M | 16.90M | 28.58M |
| Cash, Cash Equivalents and Short-Term Investments | 9.27M | 3.45M | 21.72M | 12.96M | 24.78M |
| Total Debt | 4.70M | 7.44M | 6.70M | 543.72K | 990.21K |
| Total Liabilities | 14.85M | 10.14M | 9.40M | 1.65M | 2.24M |
| Stockholders Equity | 5.87M | 2.30M | 18.35M | 15.24M | 26.33M |
Cash Flow | |||||
| Free Cash Flow | -19.22M | -20.21M | -11.42M | -11.14M | -8.24M |
| Operating Cash Flow | -18.69M | -19.44M | -11.28M | -10.73M | -7.93M |
| Investing Cash Flow | -630.10K | -847.76K | -143.92K | -407.48K | -306.87K |
| Financing Cash Flow | 25.14M | 2.03M | 20.18M | -681.64K | 29.70M |
Femasys Technical Analysis
Negative
3.71
Price Trends
4.22
Negative
6.35
Negative
9.99
Negative
Market Momentum
-0.40
Negative
34.64
Neutral
32.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FEMY, the sentiment is Negative. The current price of 3.71 is above the 20-day moving average (MA) of 3.20, below the 50-day MA of 4.22, and below the 200-day MA of 9.99, indicating a bearish trend. The MACD of -0.40 indicates Negative momentum. The RSI at 34.64 is Neutral, neither overbought nor oversold. The STOCH value of 32.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FEMY.
Femasys Risk Analysis
Femasys disclosed 78 risk factors in its most recent earnings report. Femasys reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Femasys Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $46.19M | -6.39 | -37.47% | ― | 64.18% | 28.90% | |
52 Neutral | $42.55M | -8.51 | -166.28% | ― | 3.37% | 15.78% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $20.06M | -3.11 | -8.45% | ― | 10.08% | 71.71% | |
47 Neutral | $4.49M | -0.91 | -70.23% | ― | 10.14% | 12.18% | |
44 Neutral | $8.03M | -0.37 | -258.08% | ― | 39.88% | 64.70% |
* Healthcare Sector Average
FEMY
Femasys
2.37
-13.14
-84.72%
RVP
Retractable Technologies
0.67
-0.15
-17.89%
MLSS
Milestone Scientific
0.48
-0.13
-20.83%
POCI
Precision Optics Corporation
4.24
-0.59
-12.22%
NXGL
NexGel Inc
0.36
-2.29
-86.34%
Femasys Corporate Events
Executive/Board ChangesShareholder Meetings
Femasys Shareholders Approve Directors and Auditor at Meeting
Positive
Jun 24, 2026
Femasys Inc. held its Annual Meeting of Stockholders on June 24, 2026, with approximately 49.26% of eligible common shares represented in person, virtually, or by proxy. At the meeting, shareholders approved the election of two Class II directors,...
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and ComplianceStock Split
Femasys Regains Nasdaq Compliance After Reverse Stock Split
Positive
Jun 24, 2026
On June 23, 2026, Femasys Inc. said it regained compliance with Nasdaq’s minimum bid price requirement for the Capital Market, closing a deficiency first flagged by the exchange in July 2025. The company met the $1.00 per share standard afte...
Delistings and Listing ChangesShareholder MeetingsStock Split
Femasys Announces 1-for-20 Reverse Stock Split Implementation
Neutral
Jun 5, 2026
On June 5, 2026, Femasys Inc. implemented a 1-for-20 reverse stock split of its common shares, following stockholder authorization at a special meeting held on April 29, 2026. Every 20 shares of issued and outstanding common stock were automatical...
Business Operations and StrategyStock Split
Femasys Announces 1-for-20 Reverse Stock Split Initiative
Neutral
Jun 4, 2026
On June 4, 2026, Femasys Inc. announced a 1-for-20 reverse stock split of its common stock, effective at 4:30 p.m. Eastern Time on June 5, 2026, with trading on a split-adjusted basis to begin on June 8, 2026 under the existing ticker FEMY and a n...
Business Operations and StrategyRegulatory Filings and Compliance
Femasys updates corporate presentation on women’s health portfolio
Positive
May 13, 2026
On May 13, 2026, Femasys Inc. posted an updated corporate slide presentation on its website, intended for use in ongoing meetings with investors, analysts and other stakeholders. The materials highlight the company’s diversified women’...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.